Literature DB >> 17113254

Mechanisms of cisplatin-induced ototoxicity and prevention.

Leonard P Rybak1, Craig A Whitworth, Debashree Mukherjea, Vickram Ramkumar.   

Abstract

Cisplatin is a widely used chemotherapeutic agent to treat malignant disease. Unfortunately, ototoxicity occurs in a large percentage of patients treated with higher dose regimens. In animal studies and in human temporal bone investigations, several areas of the cochlea are damaged, including outer hair cells in the basal turn, spiral ganglion cells and the stria vascularis, resulting in hearing impairment. The mechanisms appear to involve the production of reactive oxygen species (ROS), which can trigger cell death. Approaches to chemoprevention include the administration of antioxidants to protect against ROS at an early stage in the ototoxic pathways and the application of agents that act further downstream in the cell death cascade to prevent apoptosis and hearing loss. This review summarizes recent data that shed new light on the mechanisms of cisplatin ototoxicity and its prevention.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17113254     DOI: 10.1016/j.heares.2006.09.015

Source DB:  PubMed          Journal:  Hear Res        ISSN: 0378-5955            Impact factor:   3.208


  152 in total

1.  Real-time quantification of Xeroderma pigmentosum mRNA from the mammalian cochlea.

Authors:  O'neil W Guthrie; Franklin A Carrero-Martínez
Journal:  Ear Hear       Date:  2010-10       Impact factor: 3.570

Review 2.  Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations.

Authors:  Kristen Renee McSweeney; Laura Kate Gadanec; Tawar Qaradakhi; Benazir Ashiana Ali; Anthony Zulli; Vasso Apostolopoulos
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

Review 3.  Genetic and pharmacological intervention for treatment/prevention of hearing loss.

Authors:  Douglas A Cotanche
Journal:  J Commun Disord       Date:  2008-03-25       Impact factor: 2.288

4.  Cisplatin-mediated activation of extracellular signal-regulated kinases 1/2 (ERK1/2) by inhibition of ERK1/2 phosphatases.

Authors:  Agata Gozdz; Aruna Vashishta; Katarzyna Kalita; Erzsebet Szatmari; Jing-Juan Zheng; Shigeo Tamiya; Nicholas A Delamere; Michal Hetman
Journal:  J Neurochem       Date:  2008-07-04       Impact factor: 5.372

5.  Systemic dexamethasone for the prevention of cisplatin-induced ototoxicity.

Authors:  Sofia Waissbluth; Pezhman Salehi; Xinying He; Sam J Daniel
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-08-21       Impact factor: 2.503

6.  The effect of intratympanic vitamin C administration on cisplatin-induced ototoxicity.

Authors:  Saban Celebi; M Mustafa Gurdal; M Haluk Ozkul; Husamettin Yasar; H Huseyin Balikci
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-08-21       Impact factor: 2.503

7.  Short interfering RNA against transient receptor potential vanilloid 1 attenuates cisplatin-induced hearing loss in the rat.

Authors:  Debashree Mukherjea; Sarvesh Jajoo; Craig Whitworth; Jennifer R Bunch; Jeremy G Turner; Leonard P Rybak; Vickram Ramkumar
Journal:  J Neurosci       Date:  2008-12-03       Impact factor: 6.167

8.  Adenosine and the auditory system.

Authors:  Srdjan M Vlajkovic; Gary D Housley; Peter R Thorne
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

9.  Ototoxicity from combined Cisplatin and radiation treatment: an in vitro study.

Authors:  Wong-Kein Low; Sylvia W W Kong; Michelle G K Tan
Journal:  Int J Otolaryngol       Date:  2010-12-01

10.  Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity.

Authors:  Victoria Hellberg; Inger Wallin; Sofi Eriksson; Emma Hernlund; Elin Jerremalm; Maria Berndtsson; Staffan Eksborg; Elias S J Arnér; Maria Shoshan; Hans Ehrsson; Göran Laurell
Journal:  J Natl Cancer Inst       Date:  2008-12-30       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.